Ticker Details
Krystal Biotech, Inc. Krystal Biotech Inc is a biopharmaceutical company. It uses gene therapy treatments for patients suffering from rare debilitating disorders.
IPO Date:	September 20, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$7.6B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.95 | 2.57%
Avg Daily Range (30 D):	$3.63 | 1.41%
Avg Daily Range (90 D):	$4.43 | 1.70%

Institutional Daily Volume
Avg Daily Volume:	.16M
Avg Daily Volume (30 D):	.19M
Avg Daily Volume (90 D):	.21M

Trade Size
Avg Trade Size (Sh.):	42
Avg Trade Size (Sh.) (30 D):	25
Avg Trade Size (Sh.) (90 D):	28

Institutional Trades
Total Institutional Trades:	2,290
Avg Institutional Trade:	$4.26M
Avg Institutional Trade (30 D):	$11.4M
Avg Institutional Trade (90 D):	$10.24M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$5.39M
Avg Closing Trade (30 D):	$12.17M
Avg Closing Trade (90 D):	$11.86M
Avg Closing Volume:	41.31K

News

Mar 16, 2026 @ 8:00 PM What to Know About This Obesity Drug Developer Tha... Source: Jonathan Ponciano

Feb 22, 2026 @ 6:12 PM Nurix Stock Is Down 6% This Past Year, but One Bio... Source: Jonathan Ponciano

Feb 18, 2026 @ 10:17 PM Stock Market Today, Feb. 18: ImmunityBio Soars Aft... Source: Josh Kohn-Lindquist

Feb 13, 2026 @ 12:34 PM Soleus Adds a Significant Number of Celcuity Share... Source: Lawrence Rothman, Cfa

Feb 10, 2026 @ 1:00 PM Krystal Biotech to Report Fourth Quarter and Full ... Source: Na

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$7.08	$1.77	$7.08
Diluted EPS	$6.84	$1.7	$6.84
Revenue	$389.13M	$107.11M	$389.13M
Gross Profit
Net Income / Loss	$204.83M	$51.4M	$204.83M
Operating Income / Loss	$161.3M	$44.27M	$161.3M
Cost of Revenue
Net Cash Flow	$151.44M	$103.7M	$151.44M
PE Ratio	37.87